Compound questions

Why is semaglutide approved but retatrutide is not?

Semaglutide has completed its phase-3 program and reached approval. Retatrutide is still in phase-3 development — the compound is investigational, not rejected. Approval is expected pending phase-3 completion.

What is the difference between CJC-1295 and CJC-1295 DAC?

The 'DAC' variant uses drug-affinity-complex chemistry that covalently binds to serum albumin, extending half-life from hours to about a week. The 'No DAC' variant retains the shorter half-life and pulsatile pharmacology.

Why is PT-141 approved but Melanotan II is not?

PT-141 (bremelanotide) is a structurally-refined variant of Melanotan II with more selective MC4R activity. It completed a phase-3 program in female HSDD and was FDA-approved as Vyleesi in 2019. Melanotan II has no completed clinical program in any indication.

What is the difference between MOTS-c and SS-31?

MOTS-c is a naturally-occurring mitochondrial-derived peptide that signals from the mitochondrion outward via AMPK. SS-31 is a synthetic tetrapeptide that concentrates in the inner mitochondrial membrane and binds cardiolipin.

What makes GHK-Cu different from KPV?

GHK-Cu is a copper-carrier tripeptide that drives ECM remodelling through broad transcriptional modulation. KPV is a tripeptide fragment of α-MSH that suppresses inflammation through NF-κB inhibition. Different mechanisms, different roles in tissue-repair blends.

What is the difference between BPC-157 and TB-500?

BPC-157 addresses angiogenesis and fibroblast recruitment. TB-500 addresses cellular migration through actin regulation. Different layers of the tissue-repair cascade.